73024 Federal Register / Vol. 72, No. 246 / Wednesday, December 26, 2007 / Notices 

ESTIMATED ANNUALIZED BURDEN HOURS

Form Number of 

respondents 

Number of 

responses per 

respondent 

Average hours 

per 

response 

Referral/Consent to Contact Form (Patient) ................................................................................ 507 1 12/60 

CATI Detailed Telephone Interview ............................................................................................. 395 1 42/60 

Health Care Utilization/Sense of Community (for adult) ............................................................. 196 1 20/60 

Health Care Utilization (for parent of adolescent) ....................................................................... 50 1 20/60 

Economic Impact (adult) .............................................................................................................. 196 1 20/60 

Spielberger State-Trait Anxiety Inventory (for adult subjects) .................................................... 196 1 20/60 

Personality Diagnostic Questionnaire (PDQ–4+) (for adults) ...................................................... 196 1 42/60 

Childhood Trauma Questionnaire (for adult subjects) ................................................................ 196 1 25/60 

Traumatic Life Events Questionnaire (for adult subjects) ........................................................... 196 1 20/60 

Life Experiences Survey (for adult subjects) ............................................................................... 196 1 20/60 

Adolescent Subject Fatigue Questionnaire ................................................................................. 50 1 8/60 

Adolescent Health Questionnaire ................................................................................................ 50 1 20/60 

Symptoms Inventory .................................................................................................................... 246 1 12/60 

Medical Outcomes Study Short Form 36 .................................................................................... 246 1 20/60 

Multi-dimensional Fatigue Inventory ............................................................................................ 246 1 12/60 

Zung Self-Rating Depression Scale ............................................................................................ 246 1 20/60 

Illness Perception Questionnaire ................................................................................................. 246 1 20/60 

Davidson Trauma Scale .............................................................................................................. 246 1 12/60 

Ironson-Woods Spirituality/Religiousness Index ......................................................................... 246 1 8/60 

Illness Management Questionnaire ............................................................................................. 246 1 20/60 

Ways of Coping Questionnaire .................................................................................................... 246 1 33/60 

Social Support Questionnaire ...................................................................................................... 246 1 20/60 

Dated: December 14, 2007. 

Maryam I. Daneshvar, 

Acting Reports Clearance Officer, Centers for 

Disease Control and Prevention. 

[FR Doc. E7–24933 Filed 12–21–07; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

Statement of Organization, Functions, 

and Delegations of Authority 

Part C (Centers for Disease Control 

and Prevention) of the Statement of 

Organization, Functions, and 

Delegations of Authority of the 

Department of Health and Human 

Services (45 FR 67772–76, dated 

October 14, 1980, and corrected at 45 FR 

69296, October 20, 1980, as amended 

most recently at 72 FR 67308, dated 

November 28, 2007) is amended to 

reflect the reorganization of the Division 

of Healthcare Quality Promotion, 

National Center for Preparedness, 

Detection and Control of Infectious 

Diseases, Coordinating Center for 

Infectious Diseases, Centers for Disease 

Control and Prevention. 

Section C–B, Organization and 

Functions, is hereby amended as 

follows: Delete in their entirety the 

functional statements for the Division of 

Healthcare Quality Promotion (CVKD), 

and insert the following: 

Division of Healthcare Quality 

Promotion (CVKD). The mission of the 

Division of Healthcare Quality 

Promotion (DHQP) is to protect patients; 

protect healthcare personnel; and 

promote safety, quality, and value in 

both national and international 

healthcare delivery systems. In carrying 

out its mission, DHQP: (1) Measures, 

validates, interprets, and responds to 

data relevant to healthcare processes 

and outcomes, healthcare-associated 

infections, antimicrobial resistance, 

adverse drug events, and other related 

adverse events or medical errors in 

healthcare affecting patients and 

healthcare personnel; (2) investigates 

and responds to emerging infections and 

related adverse events among patients 

and healthcare providers, or others 

associated with the healthcare 

environment; (3) collaborates with 

academic and public health partners to 

design, develop, and evaluate the 

efficacy of interventions for preventing 

infections and reducing antimicrobial 

resistance, and related adverse events or 

medical errors; (4) develops and 

disseminates evidence-based guidelines 

and recommendations to prevent and 

control healthcare-associated infections/ 

antimicrobial resistance, and related 

adverse events or medical errors; (5) 

promotes the nationwide 

implementation of Healthcare Infection 

Control Practices Advisory Committee 

(HICPAC) recommendations and other 

evidence-based interventions to prevent 

healthcare-associated infections, 

antimicrobial resistance, and related 

adverse events or medical errors among 

patients and healthcare personnel; 

evaluates the impact of these 

recommendations and interventions 

across the spectrum of healthcare 

delivery sites; (6) develops, implements, 

and evaluates the effectiveness and 

impact of interventions to prevent 

transmission of healthcare-associated 

human immunodeficiency virus (HIV) 

and other bloodborne pathogen 

infections; (7) develops and evaluates 

diagnostic instruments and novel 

laboratory tests to detect and 

characterize antimicrobial-resistant 

bacterial pathogens and the infections 

that they cause; (8) promotes high 

standards of water quality in healthcare 

settings and tests and assures the water 

quality for CCID laboratories; (9) 

conducts epidemiologic, and basic and 

applied laboratory research to identify 

new strategies to prevent infections/ 

antimicrobial resistance, and related 

adverse events or medical errors, 

especially those associated with medical 

or surgical procedures, indwelling 

medical devices, contaminated 

products, dialysis, and water; (10) 

establishes evidence-based data for 

bioterrorism preparedness, and building 

and site remediation by performing 

laboratory research on surface sampling, 

detection of bacterial bioterrorist agents 

by non-culture methods, and rapid 

detection of antimicrobial resistance in 

category A and B bacterial bioterrorist 

agents; (11) serves as the National 


pwalker on PROD1PC71 with NOTICES
Federal Register / Vol. 72, No. 246 / Wednesday, December 26, 2007 / Notices 73025 

Reference Laboratory for the 

identification and antimicrobial 

susceptibility testing of staphylococci, 

anaerobic bacteria, and those gramnegative bacilli causing healthcareassociated infections; (12) develops and 

maintains the National Healthcare 

Safety Network (NHSN), a tool for 

monitoring healthcare-associated 

infections, for measuring healthcare 

outcomes and processes, and for 

monitoring healthcare worker 

vaccination and selected health 

measures in healthcare facilities; (13) 

continually assesses rates of infections 

caused by resistant-bacteria in the U.S. 

through active surveillance, review of 

national healthcare data sets, and 

laboratory surveillance programs; (14) 

promotes the integration of the 

healthcare delivery system in federal/ 

state/local public health preparedness 

planning; (15) coordinates activities, 

guidance, and research related to 

infection control across the agency and 

with national and international 

partners; (16) collaborates with other 

CDC National Centers (NC) and partners 

to assure quality clinical microbiology 

laboratory practices through proficiency 

testing, educational programs, and 

training of personnel; (17) trains 

Epidemic Intelligence Service Officers 

and other trainees; (18) coordinates 

antimicrobial resistance activities at 

CDC; (19) represents CDC as co-chair of 

the federal Interagency Task Force on 

Antimicrobial Resistance; (20) works in 

a national leadership capacity with 

public and private organizations to 

enhance antimicrobial resistance 

prevention and control, surveillance 

and response, and applied research; (21) 

coordinates blood, organ, and other 

tissue safety at CDC; (22) represents 

CDC on the Advisory Committee on 

Blood Safety and Availability and the 

Advisory Committee on Organ 

Transplantation; and (23) works in a 

national leadership capacity with other 

public and private organizations to 

enhance blood, organ, and other tissue 

safety through coordination of 

investigation, prevention, response, 

surveillance, applied research, health 

communication, and public policy. 

Office of the Director (CVDK1). (1) 

Manages, directs, and coordinates the 

activities of the DHQP: (2) provides 

leadership and guidance on policy, 

communications/media, program 

planning and development, program 

management, and operations; (3) 

provides DHQP-wide administrative 

and program services and coordinates or 

ensures coordination with the 

appropriate NC’s and CDC staff offices 

on administrative and program matters; 

(4) provides liaison with other 

governmental agencies, international 

organizations, and other outside groups; 

(5) coordinates, in collaboration with 

the appropriate NC and CDC 

components, global health activities 

relating to the prevention of healthcareassociated infections/antimicrobial 

resistance, and related adverse events or 

medical errors; (6) coordinates 

activities, guidance, and research 

related to infection control across the 

agency and with national and 

international partners; (7) works with 

other federal agencies, state 

governments, medical societies, and 

other public and private organizations 

to promote collaboration and to 

integrate healthcare preparedness in 

federal/state/local public health 

preparedness planning; (8) develops and 

conducts healthcare preparedness 

exercises and drills; (9) leads and staffs 

the Healthcare Delivery and the 

Infection Control/Clinical Care 

functional seats in the CDC Director’s 

Emergency Operations Center; (10) 

coordinates antimicrobial resistance 

activities at CDC and represents CDC as 

co-chair of the federal Interagency Task 

Force on Antimicrobial Resistance; (11) 

works with other agencies, state 

governments, medical societies, and 

other public and private organizations 

to enhance antimicrobial resistance 

prevention and control, surveillance 

and response, and applied research; (12) 

coordinates blood, organ, and other 

tissue safety at CDC and represents CDC 

on the Advisory Committee on Blood 

Safety and Availability and the 

Advisory Committee on Organ 

Transplantation; (13) works with other 

federal agencies, state governments, and 

other public and private organizations 

to enhance blood, organ, and other 

tissue safety through coordination of 

investigation, prevention, response, 

surveillance, applied research, health 

communication, and public policy; (14) 

provides program and administrative 

support for HICPAC; and (15) advises 

the Director, NCPDCID, on policy 

matters concerning DHQP activities. 

Clinical and Environmental 

Microbiology Branch (CVKDB). (1) 

Collaborates with the Prevention and 

Response Branch to provide laboratory 

response to outbreaks and emerging 

threats associated with infections/ 

antimicrobial resistance and related 

adverse events throughout the 

healthcare delivery system; (2) provides 

comprehensive laboratory support and 

expertise for investigations of 

recognized and emerging bacterial 

agents in healthcare settings; (3) 

develops methods to assess 

contamination of environmental 

surfaces with bacterial agents of 

bioterrorism, the effectiveness of various 

water treatment strategies to control the 

intentional introduction of agents of 

bioterrorism into municipal water 

systems, and develops molecular 

methods for rapid assessment of 

antimicrobial resistance in agents of 

bioterrorism; (4) investigates novel and 

emerging mechanisms of antimicrobial 

resistance among targeted pathogens 

found in healthcare settings; (5) detects 

the toxins/virulence factors of bacteria 

causing healthcare-associated infections 

to understand their transmission and 

pathogenicity; (6) conducts research in 

collaboration with partners to develop 

new, accurate methods of detecting 

antimicrobial resistance in bacteria and 

to improve reporting of antimicrobial 

susceptibility testing results to 

physicians to improve antimicrobial 

use; (7) conducts laboratory research to 

identify new strategies to prevent 

infections/antimicrobial resistance, 

related adverse events, and medical 

errors, especially those associated with 

invasive medical devices, contaminated 

products, dialysis, and water; (8) 

evaluates commercial microbial 

identification and antimicrobial 

susceptibility testing systems and 

products and facilitates their 

improvement to provide accurate 

patient test results; (9) provides 

leadership in reducing microbiology 

laboratory errors that affect patient 

outcomes by evaluating laboratory 

proficiency and promoting laboratory 

quality improvements; (10) investigates 

the role of biofilms, particularly those 

detected in indwelling medical devices 

and medical water systems, in medicine 

and public health, and identifies novel 

methods to eliminate colonization and 

biofilm formation on foreign bodies; (11) 

investigates the role of the water 

distribution systems in healthcare 

facilities in order to understand and 

prevent waterborne healthcareassociated infections; (12) provides 

expertise, research opportunity, 

training, and laboratory support for 

investigations of infections and related 

adverse events to those in other CDC 

NCs and to our partners in areas related 

to quality clinical microbiology 

laboratory practices, investigation of 

emerging pathogens, environmental 

microbiology and bioterrorism 

preparedness. 

Prevention and Response Branch 

(CVKDC). (1) Coordinates rapid and 

effective epidemiologic response to 

strategically selected outbreaks and 

emerging threats caused by healthcareassociated infections, related adverse 


pwalker on PROD1PC71 with NOTICES
73026 Federal Register / Vol. 72, No. 246 / Wednesday, December 26, 2007 / Notices 

healthcare events, related infections in 

the community, and antimicrobial 

resistance; communicates the results 

and findings of response activities with 

federal and state agencies in order to 

alert healthcare providers and educate 

the public to prevent similar adverse 

events in the future; (2) strategically 

supports local, state, national, and 

international efforts to prevent 

healthcare-associated infections, related 

infections in the community, 

antimicrobial resistance, and related 

adverse events or medical errors using 

evidence-based recommendations and 

effective health communications 

strategies that enhance rapid and 

reliable information dissemination and 

exchange; (3) develops and/or evaluates 

the effectiveness of both experimental 

and applied interventions to prevent 

healthcare-associated infections, related 

infections in the community, 

antimicrobial resistance, blood-borne 

virus transmission, and related adverse 

events or medical errors across the 

spectrum of healthcare delivery sites; (4) 

provides epidemiology support to 

laboratory branch for investigation and 

study of both recognized and emerging 

bacterial healthcare pathogens and 

related community pathogens, including 

antimicrobial resistant forms of these 

pathogens; (5) develops, promotes, and 

monitors implementation of guidelines/ 

recommendations, and other proven 

interventions to prevent healthcareassociated infections, related infections 

in the community, blood-borne virus 

transmission, antimicrobial resistance, 

medical errors, and occupational 

infections/exposures among healthcare 

personnel; (6) develops and/or evaluates 

the effectiveness of both experimental 

and applied interventions to promote 

healthcare worker safety; (7) develops, 

promotes, and monitors implementation 

of interventions to prevent transmission 

of healthcare-associated HIV infections 

and conducts case investigations of 

occupational HIV infections; (8) 

conducts research, including applied 

epidemiologic and clinical, to prevent 

healthcare-associated infections and 

antimicrobial resistant infections; (9) 

provides expert consultation, guidance, 

and technical support to other branches 

in the division, across the agency, to 

domestic and international partners, 

and the U.S. public on the epidemiology 

and prevention of healthcare-associated 

infections, related community 

infections, antimicrobial resistance, and 

exposures/injuries among healthcare 

personnel; and (10) provides 

epidemiology support to clinical and 

environmental microbiology branch to 

identify new strategies to prevent 

adverse events due to infections 

associated with indwelling medical 

devices, contaminated products, 

dialysis, and water. 

Surveillance Branch (CVKDD). (1) 

Monitors and evaluates on the national 

level the extent, distribution, and 

impact of healthcare-associated 

infections, antimicrobial use and 

resistance, adverse drug events, 

healthcare worker safety events, and 

adherence to clinical processes and 

intervention programs designed to 

prevent or control adverse exposures or 

outcomes in healthcare; (2) provides 

leadership and consultative services for 

statistical methods and analysis to 

investigators in the Branch, Division, 

and other organizations responsible for 

surveillance, research studies, and 

prevention and control of healthcareassociated infections and other 

healthcare-associated adverse events; (3) 

improves methods and enables wider 

use of clinical performance 

measurements by healthcare facilities 

and public health entities for specific 

interventions and prevention strategies 

designed to safeguard patients and 

healthcare workers from risk exposures 

and adverse outcomes through 

collaborations with extramural partners; 

(4) collaborates with public and private 

sector partners to further standardize, 

integrate, and streamline systems by 

which healthcare organizations collect, 

manage, analyze, report, and respond to 

data on clinical guideline adherence, 

healthcare-associated infections, 

including transmission of multi-drugresistant organisms and other 

healthcare-associated adverse events; (5) 

coordinates, further develops, enables 

wider use, and maintains the NHSN, (a 

web-based system for healthcare 

facilities throughout the U.S. to collect 

and analyze their own data and share 

data with DHQP and other organizations 

on healthcare-associated adverse events 

and process-of-care measures) to obtain 

scientifically valid clinical performance 

indices and benchmarks that promote 

healthcare quality and value at the 

facility, state, and national levels; (6) 

conducts applied research to identify 

and develop innovative methods to 

detect and monitor healthcareassociated infections and antimicrobial 

resistance; (7) conducts special studies 

and provides national estimates of 

targeted, healthcare-associated adverse 

events, antimicrobial use and resistance 

patterns, and the extent to which 

prevention and control safeguards are in 

use to protect at-risk patients across the 

spectrum of healthcare delivery sites; 

and (8) uses NHSN and other data 

sources to conduct special studies and 

provide national estimates of targeted 

occupational illnesses and injuries 

among healthcare workers and the 

extent to which preventive safeguards 

are in use across the spectrum of 

healthcare delivery sites. 

Dated: December 13, 2007. 

William H. Gimson, 

Chief Operating Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. 07–6130 Filed 12–21–07; 8:45 am] 

BILLING CODE 4160–18–M 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Submission for OMB Review; 

Comment Request 

Title: National Survey of Child and 

Adolescent Well-Being-Second Cohort 

(NSCAW II). 

OMB No.: 0970–0202. 

Description: The Department of 

Health and Human Services (HHS) 

intends to collect data on a new sample 

of children and families for the National 

Survey of Child and Adolescent WellBeing (NSCAW). The NSCAW was 

authorized under Section 427 of the 

Personal Responsibility and Work 

Opportunities Reconciliation Act of 

1996. The original survey began in 

November 1999 with a national sample 

of 5,501 children, ages 0–14, who had 

been the subject of investigation by 

Child Protective Services during the 

baseline data collection period, which 

extended from November 1999 through 

April 2000. Direct assessments and 

interviews were conducted with the 

children themselves, their primary 

caregivers, their caseworkers, and, for 

school-aged children, their teachers; 

agency directors also were interviewed 

at baseline. Follow-up data collections 

were conducted 12 months, 18 months, 

and 36 months post-baseline, and a fifth 

data collection is currently under way. 

The NSCAW is the only source of 

nationally representative, firsthand 

information about the functioning and 

well-being, service needs, and service 

utilization of children and families who 

come to the attention of the child 

welfare system. Information is collected 

about children’s cognitive, social, 

emotional, behavioral, and adaptive 

functioning, as well as family and 

community factors that are likely to 

influence their functioning. Family 

service needs and service utilization 

also are addressed in the data collection. 

The current data collection plan calls 

for selecting a new cohort of 5,700 


pwalker on PROD1PC71 with NOTICES